|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 2 | Aeromonas veronii biovar veronii and sepsis-infrequent complication of biliary drainage placement: A case report显示文摘BACKGROUND Aeromonas species are uncommon pathogens in biliary sepsis and cause substantial mortality in patients with impaired hepatobiliary function. Asia has the highest incidence of infection from Aeromonas,whereas cases in the west are rare.CASE SUMMARY We report the case of a 64-year-old woman with advanced pancreatic cancer and jaundice who manifested fever,abdominal pain,severe thrombocytopenia,anemia and kidney failure following the insertion of a percutaneous transhepatic biliary drainage. Blood culture results revealed the presence of Aeromonas veronii biovar veronii(A. veronii biovar veronii). After antibiotic therapy and transfusions,the life-threatening clinical conditions of the patient improved and she was discharged.CONCLUSION This was a rare case of infection,probably the first to be reported in West countries,caused by A. veronii biovar veronii following biliary drainage. A finding of Aeromonas must alert clinician to the possibility of severe sepsis. | Manlio Monti Arianna Torri Elena Amadori Alice Rossi Giulia Bartolini Chiara Casadei Giovanni Luca Frassineti | 2019 | World Journal of Clinical Cases2019，7，6： | 4 |
| 3 | In vitro schedualdependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines显示文摘 | Ricotti L Tesei A Frassineti GL | 2003 | PClin Cancer Res2003，9，： | 1 |
| 4 | High-dose chemotherapy for triple negative breast cancer显示文摘 | GIORGI U D E ROSTI G FRASSINETI L | 2007 | Annals of Oncology2007，18，1： | 1 |
| 5 | Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin,preceded by dexrazoxane,and paclitaxel for patients with high-risk Stage Ⅱ-Ⅲ breast cancer显示文摘 | de Giorgi U Giannini M Frassineti L | | 0，，04： | 1 |
| 6 | Adjuvant sequentialmethotrexate-->5-fluorouracil vs 5-fluorouracil plus leucovorinin radically resected stageⅢand high-risk stageⅡcolon cancer显示文摘 | Sobrero A Frassineti G Falcone A | 2005 | Br J Cancer2005，92，： | 1 |
| 7 | Multilevel radiofrequency ablation for snoring and OSAHS patients therapy:long-term outcomes显示文摘 | DE VITO A FRASSINETI S PANATTA M L | 2012 | Eur Arch Otorhinolaryngol2012，269，： | 1 |
| 8 | Multilevel radiofrequency ablation for snoring and OSAHS patients therapy:longterm outcomes显示文摘 | De Vito A Frassineti S Panatta ML | 2012 | Eur Arch Otorhinolaryngol2012，269，1： | 1 |
| 9 | Potentiation of antiproliferative drug activity by onidamine in hepatocellular carcinoma cells显示文摘 | Ricotti L Tesei A De Paola F Milandri C Amadori D Frassineti GL Ulivi P Zoli W | 2003 | J Chemother2003，15，5： | 1 |
| 10 | High-dose chemotherapy for triple negative breast cancer显示文摘 | De Giorgi U Rosti G Frassineti L | 2006 | Ann Oncol2006，18，： | 1 |
| 11 | Combined transoral robotic tongue base surgery and palate surgery in obstructive sleep apnea‐hypopnea syndrome: Expansion sphincter pharyngoplasty versus uvulopalatopharyngoplasty显示文摘 | Claudio Vicini Filippo Montevecchi Kenny Pang Ahmed Bahgat Iacopo Dallan Sabrina Frassineti Aldo Campanini | 2014 | Head Neck2014，，1： | 1 |
| 12 | Multilevel radiofrequency ab- lation for snoring and OSAHS patients therapy:long-term outcomes显示文摘 | De Vito A Frassineti S Panatta ML | 2012 | Eur Arch Otorhinolaryngol2012，269，1： | 1 |
| 13 | In vivo ^31 p- MRS assess ment of cytosolic in the human skeletal muscle in different metabolic conditions显示文摘 | Lotti S Frassineti C Alderighi L | 2000 | Magn Reson Imaging2000，18，5： | 1 |
| 14 | High - dose chemother- apy for triple negative breast cancer 显示文摘 | De Giorgi U Rosti G Frassineti L | 2007 | Ann Oneol2007，18，1： | 1 |
| 15 | High-dose chemotherapy for triple negative breast cancer 显示文摘 | DE GIORGI U ROSTI G FRASSINETI L | 2007 | Ann Oncol2007，18，1： | 1 |
| 16 | Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage 11- HI breast cancer显示文摘 | De Giorgi U1 Giannini M Frassineti L | 2006 | Int J Radiat Oncol Biol Phys2006，65，4： | 1 |
| 17 | High-dose chemotherapy for triple negative breast cancer显示文摘 | De Giorgi U Rosti G Frassineti L | | 0，，01： | 1 |
| 18 | In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers 显示文摘 | Zoli W Flamigni A Frassineti GL | 1995 | Breast Cancer Res Treat1995，34，1： | 1 |
| 19 | High-dose chemotherapy for triple negative breast cancer 显示文摘 | De Giorgi U Rosti G Frassineti L | 2007 | Ann Oncol2007，18，1： | 1 |
| 20 | Multilevelradiofrequency ablation for snoring and OSAHS patientstherapy: long-term outcomes 显示文摘 | De Vito A Frassineti S Panatta M L | 2012 | Eur Arch Otorhinolar-yngol2012，269，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员